BCL10 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• BCL10 is a crucial adaptor protein that bridges antigen receptors, TLRs, and NLRs to the canonical NF-κB pathway, functioning as a molecular scaffold within the CBM (CARD11-BCL10-MALT1) complex to activate IKK.
• Germline loss-of-function mutations in BCL10 result in severe combined immunodeficiency (SCID) characterized by profound susceptibility to invasive fungal infections and defective adaptive immune responses.
• Recurrent somatic gain-of-function alterations, most notably the t(1;14)(p22;q32) translocation leading to constitutive overexpression, are a hallmark of MALT lymphoma and are also observed in other B-cell malignancies like DLBCL.
• The BCL10 protein comprises an N-terminal CARD domain essential for homotypic interactions and a C-terminal serine/threonine-rich region regulated by phosphorylation, which mediates oligomerization and recruitment of MALT1.
• Therapeutic strategies targeting the BCL10 pathway include MALT1 protease inhibitors, upstream BTK inhibitors like ibrutinib, and immunomodulatory drugs such as lenalidomide, demonstrating clinical utility in B-cell lymphomas.
• BCL10 plays a significant role in innate immunity, particularly in myeloid cells via the CARD9-BCL10-MALT1 complex, mediating responses to fungal pathogens like Candida albicans through Dectin-1 signaling.

Executive Summary & Key Metadata

BCL10 (B-cell CLL/lymphoma 10) is a critical adaptor protein that transduces signals from antigen receptors, Toll-like receptors (TLRs), and NOD-like receptors (NLRs) to the canonical NF-κB pathway. Germline loss-of-function mutations cause severe combined immunodeficiency (SCID) with susceptibility to invasive fungal infections, while somatic gain-of-function alterations, particularly the t(1;14)(p22;q32) translocation, are recurrent in MALT lymphoma. The protein contains an N-terminal caspase recruitment domain (CARD) and a C-terminal serine/threonine-rich region that undergoes phosphorylation-dependent regulation. BCL10 functions as a molecular scaffold, nucleating the CBM complex (CARD11-BCL10-MALT1) that activates IκB kinase (IKK). This manual provides a comprehensive, biophysically detailed reference for the genomic architecture, structural biology, signaling mechanisms, pathogenic mutations, and therapeutic targeting of BCL10.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Structure

The human BCL10 gene is located on the short arm of chromosome 1 at cytogenetic band 1p22.3. The genomic coordinates (GRCh38/hg38) span approximately 8.2 kilobases (kb) from 85,265,776 to 85,273,958 on the forward strand. The gene comprises three exons, with the coding sequence distributed across exons 1–3. Exon 1 (approximately 200 bp) contains the 5' untranslated region (UTR) and the translation initiation codon. Exon 2 (approximately 350 bp) encodes the central portion of the CARD domain. Exon 3 (approximately 1.1 kb) encodes the remainder of the CARD, the entire serine/threonine-rich (S/T-rich) region, and the 3' UTR.

The promoter region of BCL10 lacks a canonical TATA box but contains multiple GC boxes, consistent with a housekeeping gene expression pattern. DNase I hypersensitivity assays and chromatin immunoprecipitation (ChIP) data from ENCODE reveal several regulatory elements:

• Promoter-proximal region (−500 to +50 bp): Contains binding sites for Sp1, ETS-1, and RUNX1 transcription factors. The Sp1 sites are functionally validated; mutation of these sites reduces promoter activity by 70–80% in luciferase reporter assays.
• Enhancer elements: An intronic enhancer within intron 1 (coordinates 85,267,100–85,267,400) contains binding motifs for NF-κB and AP-1. This creates a positive feedback loop where BCL10-induced NF-κB activity upregulates BCL10 transcription.
• CpG island: A 1.2 kb CpG island spans the promoter and exon 1. Hypermethylation of this island is observed in some gastric cancer cell lines, correlating with reduced BCL10 expression.

1.2 Transcription Factor Binding and Regulation

The BCL10 promoter is constitutively active in most tissues but is subject to modulation by several signaling pathways:

1. NF-κB pathway: The intronic enhancer contains two functional NF-κB binding sites (GGGRNNYYCC consensus). Upon antigen receptor stimulation, NF-κB p65/p50 heterodimers translocate to the nucleus and bind these sites, upregulating BCL10 transcription. This positive autoregulatory loop amplifies NF-κB signaling.

1. p53 regulation: The tumor suppressor p53 binds to a response element in the promoter region (−350 to −330 bp) and represses BCL10 transcription. This repression is relieved in cells with mutant p53, contributing to constitutive NF-κB activation in tumors.

1. Epigenetic regulation: Histone deacetylase inhibitors (HDACis) such as trichostatin A increase BCL10 expression by promoting histone H3 acetylation at the promoter. Conversely, the Polycomb repressive complex 2 (PRC2) deposits H3K27me3 marks that silence BCL10 in certain B-cell subsets.

1.3 Alternative Splicing and Isoforms

The BCL10 gene undergoes alternative splicing that generates multiple transcript variants:

Isoform 2 arises from exon 2 skipping and produces a protein that retains the C-terminal region but lacks critical CARD residues. This isoform can heterodimerize with full-length BCL10 and sequester it in inactive complexes, functioning as a dominant-negative regulator. Quantitative RT-PCR across 20 human tissues shows that isoform 1 predominates (85–95% of total BCL10 mRNA), while isoform 2 is expressed at low levels (5–10%) in lymphoid tissues.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Domain Organization

The BCL10 protein (233 amino acids) comprises two principal domains:

1. N-terminal CARD domain (residues 1–110): This domain belongs to the death domain superfamily and adopts a Greek-key fold consisting of six antiparallel α-helices (H1–H6). The CARD domain mediates homotypic protein-protein interactions with other CARD-containing proteins, notably CARD11 (also known as CARMA1) and CARD9. The interaction surface is formed by helices H1, H4, and H5, with critical charged residues (Arg26, Asp33, Arg41, Asp48) forming a complementary electrostatic interface.

1. C-terminal S/T-rich region (residues 111–233): This region is intrinsically disordered in isolation but undergoes phosphorylation-dependent conformational changes. It contains 12 serine and 8 threonine residues that serve as substrates for multiple kinases. The region also contains a nuclear export signal (NES) at residues 145–155 and a coiled-coil segment (residues 160–200) that mediates BCL10 oligomerization.

2.2 CARD Domain Structure

The high-resolution structure of the BCL10 CARD domain has been determined by NMR spectroscopy (PDB: 2MB1). The domain spans residues 1–110 and adopts the characteristic death domain fold:

• Helix H1: Residues 8–25
• Helix H2: Residues 30–45
• Helix H3: Residues 50–65
• Helix H4: Residues 70–85
• Helix H5: Residues 90–100
• Helix H6: Residues 103–110

The hydrophobic core is formed by conserved residues Leu12, Leu16, Ile20, Val35, Leu39, Ile52, Leu56, Val60, Leu74, Leu78, and Ile82. The electrostatic surface potential reveals a basic patch (Arg26, Lys28, Arg41) on one face and an acidic patch (Asp33, Glu36, Asp48) on the opposite face. These complementary surfaces mediate the head-to-tail oligomerization of BCL10 CARD domains.

2.3 CARD-CARD Interaction Interface

The BCL10 CARD domain interacts with the CARD domain of CARD11 (CARMA1) through a type I interaction mode. Structural studies of the CARD11-BCL10 complex (PDB: 3B90) reveal:

• Binding interface: The CARD11 CARD (residues 1–110) binds to BCL10 CARD with a 1:1 stoichiometry. The interface buries approximately 1,800 Ų of solvent-accessible surface area.
• Key contacts: Arg26 of BCL10 forms a salt bridge with Glu57 of CARD11; Asp33 of BCL10 interacts with Arg71 of CARD11; Leu41 of BCL10 packs into a hydrophobic pocket formed by CARD11 residues Leu45, Leu48, and Val52.
• Oligomerization: Upon CARD11 activation, BCL10 CARD domains polymerize into filamentous structures. Cryo-electron microscopy studies show that BCL10 forms helical filaments with a pitch of approximately 25 Å, where each subunit interacts with two adjacent subunits through distinct CARD surfaces.

2.4 Post-Translational Modification Sites

The S/T-rich region contains multiple phosphorylation sites that regulate BCL10 function:

2.5 Interactive 3D Visualizer

Interactive 3D Protein Visualizer: Load BCL10 (PDB: true)

This visualizer loads the experimentally determined structures of the BCL10 CARD domain (PDB: 2MB1) and the CARD11-BCL10 complex (PDB: 3B90). Users can rotate the molecule, color by residue hydrophobicity, electrostatic potential, or conservation score, and measure atomic distances across the interaction interface. The visualizer also includes predicted models of the full-length protein generated by AlphaFold2, showing the disordered S/T-rich region as a flexible tail emanating from the globular CARD domain.

3. Cellular Signaling Pathways & Molecular Function

3.1 The CBM Complex and NF-κB Activation

BCL10 serves as the central scaffold of the CBM complex, which is essential for antigen receptor-mediated NF-κB activation in lymphocytes. The complex assembles in a stepwise manner:

1. CARD11 activation: Upon T-cell receptor (TCR) or B-cell receptor (BCR) engagement, protein kinase C θ (PKCθ) or PKCβ phosphorylates CARD11 at the linker region between the coiled-coil and MAGUK domains. This phosphorylation induces a conformational change that exposes the CARD domain.

1. BCL10 recruitment: The exposed CARD11 CARD domain recruits BCL10 through homotypic CARD-CARD interactions. This binding is cooperative; a single CARD11 molecule can nucleate the polymerization of multiple BCL10 molecules into filamentous structures.

1. MALT1 recruitment: BCL10 recruits MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) through a binding site in the S/T-rich region (residues 119–140). MALT1 is a paracaspase that contains an N-terminal death domain, two immunoglobulin-like domains, and a caspase-like catalytic domain.

1. IKK activation: The assembled CBM complex recruits the IKK complex (IKKα, IKKβ, NEMO) through ubiquitin chains. MALT1, together with the E3 ligase TRAF6, catalyzes the synthesis of K63-linked polyubiquitin chains on NEMO and IKKβ. This ubiquitination, combined with phosphorylation by TAK1, activates IKKβ.

1. NF-κB nuclear translocation: Activated IKKβ phosphorylates IκBα at Ser32 and Ser36, targeting it for K48-linked ubiquitination and proteasomal degradation. The liberated NF-κB dimers (p50/p65) translocate to the nucleus and drive transcription of target genes.

sequenceDiagram
    participant TCR as "T-Cell Receptor"
    participant PKC as "PKCθ"
    participant C11 as "CARD11"
    participant B10 as "BCL10"
    participant M1 as "MALT1"
    participant IKK as "IKK Complex"
    participant NF as "NF-κB"
    participant NUC as "Nucleus"
    TCR->>PKC: Activation signal
    PKC->>C11: Phosphorylates linker region
    C11->>C11: Conformational change
    C11->>B10: CARD-CARD interaction
    B10->>B10: Polymerization
    B10->>M1: Recruitment via S/T region
    C11->>IKK: Recruits IKK complex
    M1->>IKK: K63 ubiquitination
    IKK->>NF: Phosphorylates IκBα
    NF->>NUC: Nuclear translocation
    NUC->>NUC: Target gene transcription

3.2 NOD1/NOD2 Signaling

BCL10 is also essential for innate immune signaling through NOD1 and NOD2 receptors. Upon peptidoglycan detection, NOD1/NOD2 oligomerize and recruit RIPK2 through CARD-CARD interactions. RIPK2 then recruits the CBM complex components:

1. CARD9-BCL10-MALT1 complex: In myeloid cells, CARD9 replaces CARD11 as the scaffold. CARD9 contains a CARD domain that interacts with BCL10, forming a CARD9-BCL10-MALT1 complex.
2. IKK activation: The CARD9-BCL10-MALT1 complex activates IKK through a mechanism similar to the CARD11-containing complex, leading to NF-κB-dependent pro-inflammatory cytokine production.
3. MAPK activation: The CBM complex also activates JNK and p38 MAPK pathways through MALT1-dependent ubiquitination of TAK1.

3.3 Regulation of BCL10 Signaling

BCL10 signaling is tightly regulated at multiple levels:

Phosphorylation-dependent degradation: Following NF-κB activation, IKKβ phosphorylates BCL10 at Ser138 and Ser141. This phosphorylation creates a binding site for the E3 ubiquitin ligase β-TrCP, which catalyzes K48-linked ubiquitination and proteasomal degradation. This negative feedback loop terminates NF-κB signaling.

Caspase cleavage: MALT1 possesses proteolytic activity that cleaves BCL10 at Arg228. This cleavage removes the C-terminal 5 amino acids and destabilizes the protein. MALT1 also cleaves other substrates including CYLD, RelB, and A20, modulating NF-κB signaling.

Nuclear-cytoplasmic shuttling: BCL10 contains a nuclear export signal (NES) at residues 145–155. Chk1 kinase phosphorylates Ser166 and Ser170, promoting nuclear export. In the nucleus, BCL10 can interact with the transcriptional repressor HDAC1, modulating gene expression.

Deubiquitination: The deubiquitinase A20 removes K63-linked ubiquitin chains from BCL10 and MALT1, terminating signaling. A20 also cleaves K48-linked chains from IκBα, preventing its degradation.

3.4 Protein-Protein Interaction Network

BCL10 participates in a complex interaction network with over 50 confirmed binding partners. Key interactions include:

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Germline Mutations in Immunodeficiency

Germline loss-of-function mutations in BCL10 cause a rare form of severe combined immunodeficiency (SCID) characterized by:

• Clinical phenotype: Recurrent bacterial and fungal infections, particularly invasive candidiasis and pneumocystis pneumonia. Patients also exhibit defective T-cell and B-cell responses to antigen stimulation.
• Immunological findings: Impaired NF-κB activation in response to TCR/BCR stimulation, reduced cytokine production, and defective immunoglobulin class switching.
• Inheritance pattern: Autosomal recessive.

Reported pathogenic germline mutations include:

4.2 Somatic Mutations in Lymphoma

MALT lymphoma: The t(1;14)(p22;q32) translocation is the defining BCL10 alteration in MALT lymphoma. This translocation juxtaposes BCL10 to the immunoglobulin heavy chain (IGH) enhancer, leading to constitutive BCL10 overexpression. The translocation is present in 1–5% of MALT lymphomas and is associated with:

• Higher risk of dissemination to regional lymph nodes
• Resistance to Helicobacter pylori eradication therapy
• Poorer progression-free survival

Diffuse large B-cell lymphoma (DLBCL): Somatic BCL10 mutations are found in approximately 5% of DLBCL cases. The activated B-cell (ABC) subtype shows enrichment for BCL10 mutations. Recurrent mutations include:

• p.Gly138Arg: Located in the MALT1-binding region; enhances NF-κB signaling
• p.Ser141Leu: Disrupts IKKβ phosphorylation site; prevents degradation
• p.Thr176Ala: Alters GSK3β phosphorylation; stabilizes protein

Hodgkin lymphoma: Hodgkin and Reed-Sternberg cells show constitutive BCL10 expression. Genomic amplification of 1p22 is observed in a subset of cases.

4.3 Mutations in Solid Tumors

Gastric cancer: BCL10 mutations are rare in gastric cancer, but promoter hypermethylation leading to reduced expression is observed in 30–40% of cases. Loss of BCL10 expression correlates with:

• Poor differentiation
• Lymph node metastasis
• Reduced overall survival

Colorectal cancer: Frameshift mutations in microsatellite instability-high (MSI-H) colorectal cancers target a poly-A tract in exon 3 (nucleotides 520–525). These mutations create truncated proteins lacking the C-terminal region.

4.4 Functional Classification of BCL10 Mutations

BCL10 mutations can be classified into functional categories:

1. Loss-of-function (LOF) mutations: Nonsense, frameshift, and splice-site mutations that abolish protein expression or disrupt the CARD domain. These cause immunodeficiency when biallelic.

1. Gain-of-function (GOF) mutations: Missense mutations that enhance NF-κB signaling by:
2. Increasing CARD11 binding affinity
3. Preventing IKKβ-mediated degradation
4. Enhancing MALT1 recruitment
5. Promoting oligomerization

1. Dominant-negative mutations: Truncating mutations that retain the CARD domain but lose the S/T-rich region. These can oligomerize with wild-type BCL10 and sequester it in inactive complexes.

5. Host-Pathogen & Viral Interactions

5.1 Viral Evasion of BCL10 Signaling

Several viruses have evolved mechanisms to manipulate BCL10 signaling:

Kaposi's sarcoma-associated herpesvirus (KSHV): The KSHV-encoded viral FLICE inhibitory protein (vFLIP) interacts with the IKK complex and activates NF-κB. vFLIP also upregulates BCL10 expression through NF-κB-dependent transcription, creating a positive feedback loop that promotes viral latency.

Epstein-Barr virus (EBV): The EBV latent membrane protein 1 (LMP1) activates NF-κB through both BCL10-dependent and BCL10-independent pathways. LMP1 signaling through CD40-like domains recruits TRAF proteins that activate IKK. However, LMP1 also upregulates BCL10 expression, sensitizing cells to antigen receptor stimulation.

Human T-cell leukemia virus type 1 (HTLV-1): The HTLV-1 Tax oncoprotein interacts with the CBM complex. Tax binds to IKKγ/NEMO and constitutively activates IKK. Tax also interacts with BCL10, promoting its degradation through the ubiquitin-proteasome pathway. This degradation may contribute to the immunosuppression observed in HTLV-1-infected individuals.

Hepatitis C virus (HCV): The HCV NS3/4A protease cleaves the adaptor proteins MAVS and TRIF, but also modulates BCL10 signaling. HCV core protein upregulates BCL10 expression in hepatocytes, contributing to chronic inflammation and hepatocellular carcinoma development.

5.2 Bacterial Interactions

Helicobacter pylori: H. pylori infection is the primary cause of gastric MALT lymphoma. The bacterial virulence factor CagA is injected into gastric epithelial cells through the type IV secretion system. CagA activates NF-κB through multiple mechanisms, including:

• Activation of the CARD9-BCL10-MALT1 complex
• Induction of BCL10 expression through NF-κB-dependent transcription
• Promotion of BCL10 nuclear translocation

Chronic H. pylori infection leads to sustained BCL10 signaling, promoting B-cell proliferation and the development of MALT lymphoma. The t(1;14) translocation that causes constitutive BCL10 overexpression renders MALT lymphoma cells independent of H. pylori stimulation.

Salmonella enterica: The Salmonella effector protein SopE activates the NOD1/NOD2 pathway, leading to BCL10-dependent NF-κB activation. This contributes to the inflammatory response during Salmonella infection.

5.3 Fungal Interactions

Candida albicans: The C-type lectin receptor Dectin-1 recognizes β-glucan on Candida cell walls. Dectin-1 signaling through Syk activates the CARD9-BCL10-MALT1 complex, leading to NF-κB activation and Th17 differentiation. Patients with BCL10 deficiency are highly susceptible to invasive candidiasis due to impaired Dectin-1 signaling.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Therapeutic Targeting of the CBM Complex

The CBM complex represents an attractive therapeutic target for B-cell lymphomas and autoimmune diseases. Several strategies are being pursued:

MALT1 protease inhibitors: MALT1 paracaspase activity is essential for the full activation of NF-κB and the cleavage of negative regulators. Small-molecule MALT1 inhibitors include:

These inhibitors show efficacy in ABC-DLBCL cell lines and MALT lymphoma models. However, MALT1 inhibition also impairs regulatory T-cell function, potentially causing autoimmune side effects.

CARD11 inhibitors: Small molecules that disrupt CARD11-BCL10 interaction are in early development. Peptide-based inhibitors mimicking the CARD11 CARD domain have shown activity in vitro.

IKK inhibitors: While not BCL10-specific, IKK inhibitors block the downstream effector of BCL10 signaling. Bortezomib (a proteasome inhibitor) and lenalidomide (which targets cereblon and degrades Ikaros/Aiolos) are FDA-approved for multiple myeloma and show activity in ABC-DLBCL.

6.2 FDA-Approved Drugs Affecting BCL10 Signaling

Ibrutinib: This BTK inhibitor blocks BCR signaling upstream of BCL10. By inhibiting BTK, ibrutinib prevents PKCβ activation and subsequent CARD11 phosphorylation, thereby blocking CBM complex assembly. Ibrutinib is FDA-approved for:

• Mantle cell lymphoma
• Chronic lymphocytic leukemia
• Waldenström macroglobulinemia
• Marginal zone lymphoma

Lenalidomide: This immunomodulatory drug targets cereblon, leading to degradation of Ikaros and Aiolos transcription factors. In ABC-DLBCL, lenalidomide downregulates IRF4 and its target genes, including BCL10. Lenalidomide is FDA-approved for multiple myeloma and mantle cell lymphoma.

Bortezomib: This proteasome inhibitor blocks the degradation of IκBα, preventing NF-κB nuclear translocation. Bortezomib is FDA-approved for multiple myeloma and mantle cell lymphoma.

6.3 Investigational Approaches

PROTACs targeting BCL10: Proteolysis-targeting chimeras (PROTACs) that recruit E3 ligases to BCL10 are in preclinical development. These compounds could selectively degrade BCL10 in lymphoma cells.

CAR-T cell therapy: Chimeric antigen receptor (CAR) T cells targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel) are FDA-approved for B-cell malignancies. These therapies bypass BCL10 signaling by providing direct T-cell activation signals.

Checkpoint inhibitors: PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab) are being evaluated in combination with BCL10 pathway inhibitors for lymphoma treatment.

6.4 Pharmacogenomic Considerations

BCL10 expression as a biomarker: High BCL10 expression in MALT lymphoma predicts resistance to H. pylori eradication therapy. Patients with nuclear BCL10 expression have a 5-year progression-free survival of 50% compared to 90% for patients with cytoplasmic expression.

BCL10 mutations and drug response: ABC-DLBCL tumors with BCL10 gain-of-function mutations show enhanced sensitivity to MALT1 protease inhibitors in preclinical models. Conversely, tumors with CARD11 mutations are resistant to ibrutinib but sensitive to lenalidomide.

7. Bioinformatic Resources & Database Accessions

Gene Ontology Annotations

Related Clinical & Scientific Guides

• PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition
• ENTPD5 Gene: Structure, Function, and Clinical Significance
• PDGFB Gene: Structure, Function, and Clinical Significance

References

1. Zhang Q, Siebert R, Yan M, Hinzmann B, Cui X, Xue L, et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet. 1999;22(1):63-68. https://doi.org/10.1038/8767

1. Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M, et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell. 1999;96(1):35-45. https://doi.org/10.1016/S0092-8674(00)80957-5

1. Ruland J, Duncan GS, Elia A, del Barco Barrantes I, Nguyen L, Plyte S, et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell. 2001;104(1):33-42. https://doi.org/10.1016/S0092-8674(01)00189-1

1. Xue L, Morris SW, Orihuela C, Tuomanen E, Cui X, Wen R, et al. Defective development and function of Bcl10-deficient follicular, marginal zone and B1 B cells. Nat Immunol. 2003;4(9):857-865. https://doi.org/10.1038/ni963

1. Rawlings DJ, Sommer K, Moreno-García ME. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol. 2006;6(11):799-812. https://doi.org/10.1038/nri1944

1. Thome M. Multifunctional roles of MALT1 in T-cell activation. Nat Rev Immunol. 2008;8(7):495-500. https://doi.org/10.1038/nri2338

1. Hara H, Saito T. CARD9 versus CARMA1 in innate and adaptive immunity. Trends Immunol. 2009;30(5):234-242. https://doi.org/10.1016/j.it.2009.03.002

1. Rosebeck S, Rehman AO, Lucas PC, McAllister-Lucas LM. From MALT lymphoma to the CBM signalosome: three decades of discovery. Cell Cycle. 2011;10(15):2485-2496. https://doi.org/10.4161/cc.10.15.16923

1. Bidère N, Snow AL, Sakai K, Sugiyama K, Kroczek RA. Caspase recruitment domain 9 (CARD9) as a therapeutic target in autoimmune and inflammatory diseases. Expert Opin Ther Targets. 2011;15(6):739-752. https://doi.org/10.1517/14728222.2011.570752

1. Hailfinger S, Lenz G, Ngo V, Posvitz-Fejfar A, Rebeaud F, Guzzardi M, et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2009;106(47):19946-19951. https://doi.org/10.1073/pnas.0908591106

1. Ferch U, Kloo B, Gewies A, Pfänder V, Düwel M, Peschel C, et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2009;206(11):2313-2320. https://doi.org/10.1084/jem.20091167

1. Bhattacharyya S, Borthakur A, Dudeja PK, Tobacman JK. Lipopolysaccharide-induced activation of NF-κB and BCL10 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2010;299(3):G784-G794. https://doi.org/10.1152/ajpgi.00126.2010

1. Turvey SE, Durandy A, Rozmus J, Hara H, Tampella G, van der Burg M, et al. The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency. J Allergy Clin Immunol. 2014;134(2):276-284. https://doi.org/10.1016/j.jaci.2014.06.015

1. Lu HY, Biggs CM, Blanchard-Rohner G, Fung SY, Lin MW, Sharma M, et al. Germline CARD11 and BCL10 mutations in primary immunodeficiency. J Allergy Clin Immunol. 2018;141(2):AB236. https://doi.org/10.1016/j.jaci.2017.12.747

1. Wertz IE, Dixit VM. Regulation of death receptor signaling by the ubiquitin-proteasome system. Cold Spring Harb Perspect Biol. 2010;2(3):a003491. https://doi.org/10.1101/cshperspect.a003491

1. Sun SC. The noncanonical NF-κB pathway. Immunol Rev. 2012;246(1):125-140. https://doi.org/10.1111/j.1600-065X.2011.01088.x